Nasdaq GlobeNewswire

Inspirata to Demonstrate the Omnyx® Dynamyx™ Digital Pathology Software Suite at European Congress of Pathology 2018 in Bilbao, Spain September 9-11

Del

Stop by booth B1 at the Euskalduna Conference Centre for a hands-on experience using the next-generation of the popular Omnyx Dynamyx digital pathology software.

Bilbao, Spain, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology workflow solution provider Inspirata® Europe, Ltd. announced today that it will be an active participant at the upcoming European Congress of Pathology (ECP) 2018 conference in Bilbao, Spain September 8-11. Inspirata will be demonstrating its regulatory-cleared digital pathology solutions that are now available throughout the European Union.

With its deployment and ongoing management of North America’s largest digital pathology workflow solution, located on site at the James Cancer Hospital at the Ohio State University in Columbus, Ohio, Inspirata has become a catalyst for growth in the rapidly evolving digital pathology market. The company’s novel solution-as-a-service approach combined with its recent acquisition of the Omnyx best-of-breed digital pathology software, Dynamyx, means Inspirata is backed by more than a decade of innovation, a global install base and unparalleled industry thought leadership.

ECP attendees will be able to participate in live demos of the Dynamyx software, which features a bi-directional interface to the LIMS for instant access to patient information, gives pathologists advanced tools that promote collaboration, boosts efficiency and helps accelerate transformative care for patients. Supporting remote viewing to help with workload balancing, rapid quality assurance and second opinions, as well as molecular pathology test ordering and reporting, etc., Dynamyx empowers pathologists to spend less time searching for information and more time rendering a more accurate and rapid diagnoses.

In addition to in-booth software demonstrations, Inspirata will host Professor Rainer Grobholz, who leads the pathology department of the Government Hospital of Kantonsspital Aarau, located in Aarau in Switzerland. Professor Grobholz has been an early adopter of the Omnyx digital pathology solution and will be on hand Monday morning from 9:45-10:15 September 10th to provide testimonial accounts of the use cases his department has employed since adopting the solution in 2013.

“The Dynamyx software has helped us meet the demands of ever-increasing caseloads and dealing with the increasing shortage of pathologists,” says Professor Grobholz. “It provides a unique viewing experience not possible with glass slides and includes efficiency-enhancing tools that save us time by auto aligning the same area across multiple stains and minimizing the time it takes to pan and zoom so we can quickly navigate to tissue sections.”

About European Congress of Pathology

The European Society of Pathology and the Spanish Society of Pathology are the co-organizers of the 30th European Congress of Pathology (ECP 2018) in Bilbao, Spain being held September 8-12 at the Euskalduna Conference Centre next to the river Nervión. Pathologists and scientists from all over the world attend the annual event to be updated on all aspects of diagnostic and molecular pathology. The 2018 event marks ECP’s 30th anniversary. The theme for the event is “Pathology: Path to Precision medicine.” It will highlight pathology as the cornerstone of precision medicine and underline the central role of the pathologist in the multidisciplinary teams that guide patient management in the 21st century.

About Inspirata, Inc.

Inspirata®, Inc. provides oncology diagnostics workflow solutions that span digital pathology; diagnostic and predictive assays; and precision medicine. It also offers cancer informatics workflows that, in combination with its Natural Language Processing (NLP) and Artificial Intelligence (AI) algorithms structures unstructured case files and clinician notes to provide key insights for oncology-specific clinical and operational activities as well as cancer reporting. Inspirata’s flagship solution is its Cancer Information Data Trust (CIDT) that generates a longitudinal view of oncology patients—from diagnosis, through treatments and therapies, to outcomes. The CIDT has extensive applications in clinical decision support, research, education, drug discovery and clinical trials enrollment. Its use will extend to physicians, patients, researchers, pharma and others. For more information, please visit www.inspirata.com or contact info@inspirata.com.

Attachment

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

MindManager 2019 Empowers Professionals and Teams to Uncover Possibilities, Unite People, and Unleash Productivity26.9.2018 15:00Pressemelding

With new ways to visualize complex information, intelligent automation to speed your workflow, and added views to quickly draw connections and keep on track, MindManager 2019 delivers control, clarity, and structure to drive alignment and success OTTAWA, Ontario, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Launching today, MindManager® 2019 for Windows gives enterprises and business professionals powerful new ways to transcend the limits on what they can see, create, communicate, and achieve. The industry’s most robust and customizable information visualization software now delivers a wealth of new capabilities, including SmartRules™ to automate processes and workflows; Smart Shapes to enrich, clarify, and expand shared information; and powerful Tag and Icon views that make it easy to get a 360-degree perspective on your projects, work, and world. "Our latest release focuses on our users’ productivity and success with new features that help them deliver meaning and impact to their content, see

CrownBio Completes Validation of Prostate Cancer Patient-Derived Xenograft (PDX) Models26.9.2018 14:00Pressemelding

Unique well-characterized prostate models derived from castration resistant and hormone sensitive primary tissue now available for studies SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has announced the addition of unique, well characterized, fully annotated patient-derived xenograft (PDX) models of prostate cancer. Prostate cancer is the second most common cancer in males, impacting more than 1 million new patients worldwide each year. The disease has long been underrepresented at the preclinical modeling stage of drug development, due to the difficulty in establishing PDX models. CrownBio is committed to providing clinically relevant solutions for diseases with high unmet need. PDX are the most translatable preclinical models currently available, directly derived from patient tissue and reflectin

XBiotech Announces Granting of European Patent for Treatment of Inflammatory Skin Diseases26.9.2018 14:00Pressemelding

Broad European Patent Issued Supports XBiotech’s Skin Disease Program for Monoclonal Antibody Bermekimab AUSTIN, Texas, Sept. 26, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the European Patent Office has granted XBiotech a patent (Patent Number EP2694107) that covers the use of bermekimab as a treatment for inflammatory skin diseases. The patent includes data from studies showing that antibodies which specifically neutralize the activity of interleukin-1alpha (IL-1α) can reduce skin inflammation and treat inflammatory skin diseases. XBiotech has conducted a number of clinical trials in dermatology using bermekimab (an anti- IL-1α antibody), including ongoing studies in hidradenitis suppurativa and atopic dermatitis. XBiotech has also published clinical findings for the use of bermekimab for treatment of psoriasis and acne. The development of bermekimab for the treatment of inflammatory skin disorders is an important part of XBiotech’s commercialization p

OTP Bank Selects eGain’s Knowledge Management for Customer Service26.9.2018 12:30Pressemelding

eGain’s AI and knowledge management solution will be deployed at the bank’s contact centres and retail branches with the support of eGain partner Pattern Digital Consulting SUNNYVALE, Calif. and NEWBURY, United Kingdom, Sept. 26, 2018 (GLOBE NEWSWIRE) -- eGain (NASDAQ: EGAN), the leading provider of cloud-based customer engagement solutions today announced that OTP Bank, one of the largest banks serving Central and Eastern Europe, has selected eGain for omnichannel customer service. Pattern Digital Consulting Ltd., an implementation partner for eGain, will work with eGain Quick Value Services™ team to deploy eGain’s award-winning solution for AI-infused knowledge to provide conversational, procedural, and process guidance to agents at the bank’s contact centers and retail branches. The bank tried out eGain’s solution as part of eGain Try+Buy™ consumption model, which is a risk-free production pilot with no obligation to buy and no-charge guidance for success. Happy with the agent exper

Canadian Natural Resources Limited Announces Completion of the Extension Period to Acquire All Issued and Outstanding Shares of Laricina Energy Ltd.26.9.2018 11:00Pressemelding

CALGARY, Alberta, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Canadian Natural Resources Limited (“Canadian Natural" or the "Company") announces that Canadian Natural's offer to acquire all of the issued and outstanding common shares (the “Laricina Shares") of Laricina Energy Ltd. (“Laricina”) for $0.0815 per Laricina Share by way of a take-over bid (the "Offer"), as extended on September 13, 2018 for the mandatory 10-day extension period, expired at 11:59 p.m. (Mountain Daylight Time) on September 24, 2018. Since Canadian Natural's initial take up of 568,724,430 Laricina Shares on September 13, 2018, Computershare Investor Services Inc., the depositary, has reported that as at 11:59 p.m. (Mountain Daylight Time) on September 24, 2018, an additional 3,594,872 Laricina Shares (the "Additional Shares") were validly deposited under the Offer and not withdrawn. Canadian Natural has taken up and accepted for payment all such Additional Shares and payment for such Additional Shares will be made as so

Juniper Systems Unveils New Cedar CP3 Rugged Smartphone26.9.2018 06:36Pressemelding

BIRMINGHAM, United Kingdom, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Juniper Systems Limited today announced the release of its newest Cedar™ device, the Cedar CP3™ Rugged Smartphone. The rugged smartphone arrives two years after its predecessor, the CT5™ Rugged Smartphone, bringing massive upgrades to nearly every specification. The CP3 touts battery life of 14-16 hours operating at full brightness and while running GPS. The CP3 is powered by a Snapdragon 653 octa-core processor, delivering fast load times and top-tier performance for advanced tasks without draining the battery. ‘Rugged doesn’t have to mean bulky and slow’, said Simon Bowe, general manager of Juniper Systems Limited. ‘The CP3 proves that smartphones can be purpose-built for data collection in the world’s toughest environments – and are also handy for surfing online at home’. The Cedar CP3 Rugged Smartphone is available globally and works on any GSM network. The powerful battery delivers a shocking 480-hour standby time and

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom